An antibody’s presence in the blood does not show how evenly it reaches a tumour. Supply from vessels, movement through tissue, binding and removal all affect where it goes.
Antibody penetration describes movement and distribution from the circulation into tumour tissue. Crossing the vessel wall, moving between cells, binding a target, and uptake or clearance are separate processes. Their balance can create uneven distribution. A high concentration near a vessel does not establish exposure throughout the tumour, and a target-positive biopsy does not measure drug delivery.
There is no single reach distance supplied by the word antibody or by a tissue section. Antibody distribution and the spread of a released conjugate payload are also different measurements. Specific studies can support a delivery hypothesis; a response predictor needs validation in the intended product and clinical setting.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares Bystander effect (ADC), Antibody-drug conjugate (ADC).
Shares Bystander effect (ADC), Antibody-drug conjugate (ADC).
Shares Bystander effect (ADC), Antibody-drug conjugate (ADC).
Shares Bystander effect (ADC), Antibody-drug conjugate (ADC).
Shares Bystander effect (ADC), Antibody-drug conjugate (ADC).
Shares Bystander effect (ADC), Antibody-drug conjugate (ADC).
Shares Bystander effect (ADC), Antibody-drug conjugate (ADC).
Shares Bystander effect (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/